首页> 中文期刊>中国药房 >参附注射液联合丹参川芎嗪注射液治疗慢性肺源性心脏病心力衰竭的临床观察

参附注射液联合丹参川芎嗪注射液治疗慢性肺源性心脏病心力衰竭的临床观察

     

摘要

目的:观察参附注射液联合丹参川芎嗪注射液治疗慢性肺源性心脏病(肺心病)心力衰竭的临床疗效和安全性。方法:100例肺心病心力衰竭患者随机均分为对照组和观察组。对照组患者给予解痉平喘、低流量氧疗、消炎、利尿强心、维持机体水和电解质平衡、血管活性药物、多巴胺等常规治疗;观察组患者在对照组治疗基础上给予参附注射液50 ml和丹参川芎嗪注射液10 ml,分别加入5%葡萄糖注射液250 ml中静脉滴注,每日1次。两组患者疗程均为14 d。观察两组患者的临床疗效、临床症状体征改善时间,治疗前后血氧分压[p(O2)]、二氧化碳分压[p(CO2)]、每搏输出量(SV)、左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVSD)及不良反应发生情况。结果:观察组患者总有效率显著高于对照组,临床症状体征改善时间均显著短于对照组,差异均有统计学意义(P<0.05)。治疗后,两组患者p(O2)、p(CO2)、SV、LVEF、LVEDD、LVSD均显著优于同组治疗前,且观察组优于对照组,差异均有统计学意义(P<0.05)。两组患者均未见明显不良反应发生。结论:在常规治疗基础上以参附注射液联合丹参川芎嗪注射液治疗肺心病心力衰竭的临床疗效更显著,且安全性相当。%OBJECTIVE:To observe the clinical efficacy and safety of Shenfu injection combined with Danshen chuanxiongqin injection in the treatment of chronic pulmonary heart disease patients with heart failure. METHODS:Totally 100 chronic pulmonary heart disease patients with heart failure were randomly divided into observation group and control group. Patients in control group were given routine treatment,including antispasmodic asthma,low-flow oxygen therapy,anti-inflammatory,diuretic strong heart, maintaining the body water,electrolyte balance,vasoactive drugs and dopamine,etc. Patients in observation group were given Shenfu injection 50 ml and Danshen chuanxiongqin injection 10 ml adding into 5% glucose injection 250 ml based on the treatment of control group,iv,once a day. The course of both was 14 d. The clinical data was observed,including clinical efficacy,improve-ment time of signs and symptoms,p(O2),p(CO2),SV,LVEF,LVEDD,LVSD and the incidence of adverse reactions before and after treatment. RESULTS:The total effective rate in observation group was significantly higher than control group,the remission time of cyanosis,slowing time of heart rate and subsided time of swelling were significantly shorter than control group,with signif-icant differences(P<0.05). After treatment,the p(O2),p(CO2),SV,LVEF,LVEDD and LVSD in 2 groups were significantly bet-ter than before,and observation group was better than control group,with significant differences(P<0.05). There were no obvious adverse reactions during treatment. CONCLUSIONS:Based on the treatment,Shenfu injection combined with Danshen chuanxion-gqin injection has better clinical efficacy than routine treatment in the treatment of chronic pulmonary heart disease patients with heart failure,with similar safety.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号